{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:18:36Z","timestamp":1753737516130,"version":"3.37.3"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0222522","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T17:28:45Z","timestamp":1568741325000},"page":"e0222522","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8151-7770","authenticated-orcid":true,"given":"Wei-Nung","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Feng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hsiang","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Chuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6770-1598","authenticated-orcid":true,"given":"Jia-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"pone.0222522.ref001","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade\u2122(Bortezomib)","volume":"22","author":"J Adams","year":"2004","journal-title":"Cancer Invest"},{"key":"pone.0222522.ref002","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1365-2141.1999.01480.x","article-title":"Time trends in incidence of hematological malignancies and related conditions","volume":"106","author":"R Cartwright","year":"1999","journal-title":"Br J Haematol"},{"key":"pone.0222522.ref003","doi-asserted-by":"crossref","first-page":"e0167227","DOI":"10.1371\/journal.pone.0167227","article-title":"Prevalence and mortality-related factors of multiple myeloma in Taiwan","volume":"11","author":"JH Chen","year":"2016","journal-title":"PloS one"},{"key":"pone.0222522.ref004","doi-asserted-by":"crossref","first-page":"d637","DOI":"10.1136\/bmj.d637","article-title":"A publicly available database accelerates academic production","volume":"342","author":"YC Chen","year":"2011","journal-title":"BMJ"},{"key":"pone.0222522.ref005","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"SK Kumar","year":"2008","journal-title":"Blood"},{"key":"pone.0222522.ref006","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)","volume":"23","author":"E Kastritis","year":"2009","journal-title":"Leukemia"},{"key":"pone.0222522.ref007","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"JA Snowden","year":"2011","journal-title":"Br J Haematol"},{"key":"pone.0222522.ref008","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cncr.22850","article-title":"Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years","volume":"110","author":"SY Huang","year":"2007","journal-title":"Cancer"},{"key":"pone.0222522.ref009","unstructured":"National Health Insurance Research Database, Taiwan, (2015), http:\/\/nhird.nhri.org.tw\/en\/index.htm."},{"key":"pone.0222522.ref010","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"RA Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"pone.0222522.ref011","unstructured":"Longitudinal Health Insurance Database (LHID), https:\/\/nhird.nhri.org.tw\/en\/Data_Subsets.html. 2010."},{"key":"pone.0222522.ref012","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"SV Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"pone.0222522.ref013","first-page":"3412","article-title":"International staging system for multiple myeloma","volume":"23","author":"P.R. Greipp","year":"2005"},{"key":"pone.0222522.ref014","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","article-title":"Proteasome inhibitors in cancer therapy: lessons from the first decade","volume":"14","author":"RZ Orlowski","year":"2008","journal-title":"Clin Cancer Res"},{"key":"pone.0222522.ref015","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"RC Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"pone.0222522.ref016","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10","author":"PF Bross","year":"2004","journal-title":"Clin Cancer Res"},{"key":"pone.0222522.ref017","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.canep.2018.06.003","article-title":"Epidemiology of multiple myeloma in Taiwan, a population based study","volume":"55","author":"CH Tang","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"pone.0222522.ref018","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1658-3876(09)50006-4","article-title":"Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, stem cell transplantation and new treatment agents","volume":"2","author":"CK Lin","year":"2009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"pone.0222522.ref019","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"M Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"pone.0222522.ref020","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"PG Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"pone.0222522.ref021","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"PG Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0222522.ref022","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"JF San Miguel","year":"2008","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0222522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T04:05:40Z","timestamp":1588997140000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0222522"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0222522","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,9,17]]}}}